{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:01:17Z","timestamp":1788951677469,"version":"build-2803163510"},"reference-count":140,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology Clinics of North America"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.gtc.2021.04.003","type":"journal-article","created":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T22:14:07Z","timestamp":1626992047000},"page":"611-637","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Medical Therapies for Diarrhea-Predominant Irritable Bowel Syndrome"],"prefix":"10.1016","volume":"50","author":[{"given":"Gregory S.","family":"Sayuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.gtc.2021.04.003_bib1","first-page":"1393","article-title":"Bowel disorders","volume":"150","author":"Mearin","year":"2016","journal-title":"Gastroenterology; section ii: fgids: diagnostic groups bowel"},{"issue":"7","key":"10.1016\/j.gtc.2021.04.003_bib2","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.cgh.2012.02.029","article-title":"Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis","volume":"10","author":"Lovell","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.gtc.2021.04.003_bib3","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1136\/gutjnl-2015-311240","article-title":"The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review","volume":"66","author":"Sperber","year":"2017","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.gtc.2021.04.003_bib4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11894-017-0554-0","article-title":"Update on Rome IV criteria for colorectal disorders: implications for clinical practice","volume":"19","author":"Simren","year":"2017","journal-title":"Curr Gastroenterol Rep"},{"issue":"6","key":"10.1016\/j.gtc.2021.04.003_bib5","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1038\/ajg.2016.574","article-title":"Comparison of symptoms, healthcare utilization, and treatment in diagnosed and undiagnosed individuals with diarrhea-predominant irritable bowel syndrome","volume":"112","author":"Sayuk","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.gtc.2021.04.003_bib6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12955-017-0611-2","article-title":"Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea","volume":"15","author":"Buono","year":"2017","journal-title":"Health Qual Life Outcomes"},{"issue":"26","key":"10.1016\/j.gtc.2021.04.003_bib7","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1056\/NEJMra1607547","article-title":"Irritable bowel syndrome","volume":"376","author":"Ford","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/j.gtc.2021.04.003_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41395-018-0084-x","article-title":"American College of Gastroenterology Monograph on management of irritable bowel syndrome","volume":"113","author":"Ford","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.gtc.2021.04.003_bib9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.14309\/ajg.0000000000001036","article-title":"ACG clinical guideline: management of irritable bowel syndrome","volume":"116","author":"Lacy","year":"2021","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.gtc.2021.04.003_bib10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s12325-019-01116-z","article-title":"Current US Food and Drug Administration-Approved Pharmacologic therapies for the treatment of irritable bowel syndrome with diarrhea","volume":"37","author":"Brenner","year":"2020","journal-title":"Adv Ther"},{"issue":"21","key":"10.1016\/j.gtc.2021.04.003_bib11","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1001\/jama.287.21.2813","article-title":"Reporting number needed to treat and absolute risk reduction in randomized controlled trials","volume":"287","author":"Nuovo","year":"2002","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.gtc.2021.04.003_bib12","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1742-7843.2006.pto_412.x","article-title":"Number-needed-to-treat (NNT)--needs treatment with care","volume":"99","author":"Christensen","year":"2006","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"10.1016\/j.gtc.2021.04.003_bib14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1004409","article-title":"Rifaximin therapy for patients with irritable bowel syndrome without constipation","volume":"364","author":"Pimentel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.gtc.2021.04.003_bib15","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1053\/j.gastro.2016.08.003","article-title":"Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome","volume":"151","author":"Lembo","year":"2016","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.gtc.2021.04.003_bib16","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/apt.15001","article-title":"Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome","volume":"48","author":"Ford","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.gtc.2021.04.003_bib17","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1053\/j.gastro.2014.09.001","article-title":"American Gastroenterological Association Institute Guideline on the pharmacological management of irritable bowel syndrome","volume":"147","author":"Weinberg","year":"2014","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.gtc.2021.04.003_bib18","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.amjmed.2011.08.026","article-title":"Evaluation of harm in the pharmacotherapy of irritable bowel syndrome","volume":"125","author":"Shah","year":"2012","journal-title":"Am J Med"},{"issue":"5","key":"10.1016\/j.gtc.2021.04.003_bib20","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/j.1476-5381.2012.02068.x","article-title":"Modulation of gastrointestinal function by MuDelta, a mixed micro opioid receptor agonist\/micro opioid receptor antagonist","volume":"167","author":"Wade","year":"2012","journal-title":"Br J Pharmacol"},{"issue":"3","key":"10.1016\/j.gtc.2021.04.003_bib21","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJMoa1505180","article-title":"Eluxadoline for irritable bowel syndrome with diarrhea","volume":"374","author":"Lembo","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.gtc.2021.04.003_bib22","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/ajg.2017.72","article-title":"Eluxadoline efficacy in IBS-D patients who report prior loperamide use","volume":"112","author":"Lacy","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"10.1016\/j.gtc.2021.04.003_bib23","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.14309\/ajg.0000000000000327","article-title":"Efficacy and safety of eluxadoline in patients with irritable bowel syndrome with diarrhea who report inadequate symptom control with loperamide: RELIEF phase 4 study","volume":"114","author":"Brenner","year":"2019","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.gtc.2021.04.003_bib24","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/ajg.2016.542","article-title":"Safety of eluxadoline in patients with irritable bowel syndrome with diarrhea","volume":"112","author":"Cash","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2021.04.003_bib25","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.2147\/DDDT.S216056","article-title":"Update on eluxadoline for the treatment of irritable bowel syndrome with diarrhea: patient selection and perspectives","volume":"14","author":"Liu","year":"2020","journal-title":"Drug Des Devel Ther"},{"issue":"5","key":"10.1016\/j.gtc.2021.04.003_bib28","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1365-2036.2012.05208.x","article-title":"Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS","volume":"36","author":"Cremonini","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.gtc.2021.04.003_bib30","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1111\/j.1572-0241.2001.04128.x","article-title":"Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome","volume":"96","author":"Lembo","year":"2001","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"10.1016\/j.gtc.2021.04.003_bib31","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1111\/j.1572-0241.2007.01282.x","article-title":"A\u00a0randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5\u00a0mg and 1\u00a0mg alosetron in women with severe diarrhea-predominant IBS","volume":"102","author":"Krause","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2021.04.003_bib32","doi-asserted-by":"crossref","DOI":"10.1177\/1756284818771674","article-title":"Alosetron use in clinical practice: significant improvement in irritable bowel syndrome symptoms evaluated using the US Food and Drug Administration composite endpoint","volume":"11","author":"Lacy","year":"2018","journal-title":"Therap Adv Gastroenterol"},{"issue":"8","key":"10.1016\/j.gtc.2021.04.003_bib33","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0025-6196(12)60797-6","article-title":"Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study","volume":"67","author":"Steadman","year":"1992","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"10.1016\/j.gtc.2021.04.003_bib34","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1046\/j.1365-2036.1996.30172000.x","article-title":"Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia?","volume":"10","author":"Maxton","year":"1996","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.gtc.2021.04.003_bib35","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1136\/gutjnl-2013-305989","article-title":"A\u00a0randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea","volume":"63","author":"Garsed","year":"2014","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.gtc.2021.04.003_bib36","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.14309\/ajg.0000000000000727","article-title":"Bimodal release ondansetron improves stool consistency and symptomatology in diarrhea-predominant irritable bowel syndrome: a randomized, double-blind, trial","volume":"115","author":"Plasse","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"10.1016\/j.gtc.2021.04.003_bib37","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/BF03013138","article-title":"Ramosetron vs granisetron for the prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy","volume":"46","author":"Fujii","year":"1999","journal-title":"Can J Anaesth"},{"issue":"12","key":"10.1016\/j.gtc.2021.04.003_bib38","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1634\/theoncologist.2015-0128","article-title":"Ramosetron versus ondansetron in combination with aprepitant and dexamethasone for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: a multicenter, randomized phase III trial, KCSG PC10-21","volume":"20","author":"Kim","year":"2015","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.gtc.2021.04.003_bib39","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12876-017-0734-2","article-title":"Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials","volume":"18","author":"Qi","year":"2018","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"10.1016\/j.gtc.2021.04.003_bib40","first-page":"15","article-title":"The role of loperamide in gastrointestinal disorders","volume":"8","author":"Hanauer","year":"2008","journal-title":"Rev Gastroenterol Disord"},{"issue":"3","key":"10.1016\/j.gtc.2021.04.003_bib41","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2036.1987.tb00617.x","article-title":"Review: loperamide--a potent antidiarrhoeal drug with actions along the alimentary tract","volume":"1","author":"Ruppin","year":"1987","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 3","key":"10.1016\/j.gtc.2021.04.003_bib42","first-page":"S11","article-title":"Loperamide: a pharmacological review","volume":"7","author":"Baker","year":"2007","journal-title":"Rev Gastroenterol Disord"},{"issue":"5","key":"10.1016\/j.gtc.2021.04.003_bib43","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1053\/j.gastro.2014.09.002","article-title":"American Gastroenterological Association Institute Technical Review on the pharmacological management of irritable bowel syndrome","volume":"147","author":"Chang","year":"2014","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.gtc.2021.04.003_bib44","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3109\/00365529609006766","article-title":"A\u00a0double-blind placebo-controlled trial with loperamide in irritable bowel syndrome","volume":"31","author":"Efskind","year":"1996","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.gtc.2021.04.003_bib45","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3109\/00365528709091004","article-title":"Loperamide treatment of the irritable bowel syndrome","volume":"130","author":"Hovdenak","year":"1987","journal-title":"Scand J Gastroenterol Suppl"},{"key":"10.1016\/j.gtc.2021.04.003_bib46","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/00365528709091003","article-title":"Loperamide in treatment of irritable bowel syndrome--a double-blind placebo controlled study","volume":"130","author":"Lavo","year":"1987","journal-title":"Scand J Gastroenterol Suppl"},{"issue":"12","key":"10.1016\/j.gtc.2021.04.003_bib47","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1007\/s11695-012-0683-3","article-title":"Correlations of HOMA2-IR and HbA1c with algorithms derived from bioimpedance and spectrophotometric devices","volume":"22","author":"Adami","year":"2012","journal-title":"Obes Surg"},{"issue":"2S","key":"10.1016\/j.gtc.2021.04.003_bib48","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/j.japh.2016.11.011","article-title":"Adverse event detection using the FDA post-marketing drug safety surveillance system: cardiotoxicity associated with loperamide abuse and misuse","volume":"57","author":"Swank","year":"2017","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"issue":"3","key":"10.1016\/j.gtc.2021.04.003_bib50","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.cgh.2017.08.006","article-title":"Risk of pancreatitis following treatment of irritable bowel syndrome with eluxadoline","volume":"16","author":"Gawron","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.gtc.2021.04.003_bib51","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1177\/106002809603001121","article-title":"Pancreatitis caused by loperamide overdose","volume":"30","author":"Epelde","year":"1996","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.gtc.2021.04.003_bib52","series-title":"Diphenoxylate and atropine","author":"Jain","year":"2020"},{"issue":"4","key":"10.1016\/j.gtc.2021.04.003_bib53","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/01.pra.0000281491.65311.c3","article-title":"Diphenoxylate hydrochloride dependency","volume":"13","author":"Firoozabadi","year":"2007","journal-title":"J\u00a0Psychiatr Pract"},{"issue":"1","key":"10.1016\/j.gtc.2021.04.003_bib54","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00002018-199410010-00004","article-title":"Adverse effects of drugs used in the management of constipation and diarrhoea","volume":"10","author":"Gattuso","year":"1994","journal-title":"Drug Saf"},{"issue":"6","key":"10.1016\/j.gtc.2021.04.003_bib55","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/0016-5085(80)90924-5","article-title":"Double-blind cross-over study comparing loperamide, codeine and diphenoxylate in the treatment of chronic diarrhea","volume":"79","author":"Palmer","year":"1980","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.gtc.2021.04.003_bib56","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.gtc.2010.12.008","article-title":"Peripherally acting therapies for the treatment of irritable bowel syndrome","volume":"40","author":"Saad","year":"2011","journal-title":"Gastroenterol Clin North Am"},{"issue":"11","key":"10.1016\/j.gtc.2021.04.003_bib57","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1742-1241.1967.tb07119.x","article-title":"An assessment of dicyclomine hydrochloride ('Merbentyl') in the irritable colon syndrome","volume":"21","author":"Matts","year":"1967","journal-title":"Br J Clin Pract"},{"issue":"2","key":"10.1016\/j.gtc.2021.04.003_bib58","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00004836-198106000-00009","article-title":"Treatment of the irritable bowel syndrome with Bentyl (dicyclomine hydrochloride)","volume":"3","author":"Page","year":"1981","journal-title":"J\u00a0Clin Gastroenterol"},{"issue":"6160","key":"10.1016\/j.gtc.2021.04.003_bib59","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1136\/bmj.1.6160.376","article-title":"Treatment of irritable bowel syndrome with lorazepam, hyoscine butylbromide, and ispaghula husk","volume":"1","author":"Ritchie","year":"1979","journal-title":"Br Med J"},{"issue":"25","key":"10.1016\/j.gtc.2021.04.003_bib60","first-page":"488","article-title":"[The treatment of irritable colon. Efficacy and tolerance of buscopan plus, buscopan, paracetamol and placebo in ambulatory patients with irritable colon]","volume":"108","author":"Schafer","year":"1990","journal-title":"Fortschr Med"},{"issue":"12","key":"10.1016\/j.gtc.2021.04.003_bib61","first-page":"1041","article-title":"Different therapeutic regimens in irritable bowel syndrome","volume":"32","author":"Nigam","year":"1984","journal-title":"J\u00a0Assoc Physicians India"},{"issue":"3","key":"10.1016\/j.gtc.2021.04.003_bib62","first-page":"55","article-title":"Short term treatment of the irritable bowel syndrome: a placebo-controlled trial of peppermint oil against hyoscyamine","volume":"34","author":"Carling","year":"1989","journal-title":"Opuscula Medica"},{"issue":"4","key":"10.1016\/j.gtc.2021.04.003_bib63","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2017.11.279","article-title":"Neuromodulators for functional gastrointestinal disorders (disorders of gut-brain interaction): a Rome Foundation Working Team report","volume":"154","author":"Drossman","year":"2018","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.gtc.2021.04.003_bib64","first-page":"980","article-title":"Antidepressant therapy for unexplained symptoms and symptom syndromes","volume":"48","author":"O'Malley","year":"1999","journal-title":"J\u00a0Fam Pract"},{"issue":"9","key":"10.1016\/j.gtc.2021.04.003_bib65","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1136\/gut.2004.048884","article-title":"Use of psychopharmacological agents for functional gastrointestinal disorders","volume":"54","author":"Clouse","year":"2005","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.gtc.2021.04.003_bib66","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1053\/j.gastro.2006.10.026","article-title":"Neuroimaging of the brain-gut axis: from basic understanding to treatment of functional GI disorders","volume":"131","author":"Mayer","year":"2006","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.gtc.2021.04.003_bib67","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/BF02063948","article-title":"Effect of a tricyclic antidepressant on small intestinal motility in health and diarrhea-predominant irritable bowel syndrome","volume":"40","author":"Gorard","year":"1995","journal-title":"Dig Dis Sci"},{"issue":"2","key":"10.1016\/j.gtc.2021.04.003_bib68","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1053\/j.gastro.2020.05.059","article-title":"AGA clinical practice guidelines on the role of probiotics in the management of gastrointestinal disorders","volume":"159","author":"Su","year":"2020","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.gtc.2021.04.003_bib69","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1007\/s10620-009-0723-6","article-title":"Atypical antipsychotic quetiapine in the management of severe refractory functional gastrointestinal disorders","volume":"54","author":"Grover","year":"2009","journal-title":"Dig Dis Sci"},{"issue":"4","key":"10.1016\/j.gtc.2021.04.003_bib70","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/apt.15077","article-title":"Randomised clinical trial: pregabalin vs placebo for irritable bowel syndrome","volume":"49","author":"Saito","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2021.04.003_bib71","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1472-6882-8-46","article-title":"Complementary and alternative medicine use and cost in functional bowel disorders: a six month prospective study in a large HMO","volume":"8","author":"van Tilburg","year":"2008","journal-title":"BMC Complement Altern Med"},{"issue":"4","key":"10.1016\/j.gtc.2021.04.003_bib72","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1365-2036.2006.02776.x","article-title":"Systematic review: complementary and alternative medicine in the irritable bowel syndrome","volume":"23","author":"Hussain","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.gtc.2021.04.003_bib73","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nrgastro.2014.66","article-title":"Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic","volume":"11","author":"Hill","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.gtc.2021.04.003_bib74","doi-asserted-by":"crossref","first-page":"14977","DOI":"10.1038\/s41598-020-71939-2","article-title":"Compositional and functional differences of the mucosal microbiota along the intestine of healthy individuals","volume":"10","author":"Vaga","year":"2020","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.gtc.2021.04.003_bib75","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1136\/gutjnl-2019-318717","article-title":"No distinct microbiome signature of irritable bowel syndrome found in a Swedish random population","volume":"69","author":"Hugerth","year":"2020","journal-title":"Gut"},{"issue":"30","key":"10.1016\/j.gtc.2021.04.003_bib76","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.3748\/wjg.v18.i30.4012","article-title":"Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome","volume":"18","author":"Ducrotte","year":"2012","journal-title":"World J Gastroenterol"},{"issue":"5","key":"10.1016\/j.gtc.2021.04.003_bib77","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/j.1572-0241.2000.02015.x","article-title":"Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome","volume":"95","author":"Nobaek","year":"2000","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"10.1016\/j.gtc.2021.04.003_bib78","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1097\/00042737-200110000-00004","article-title":"A\u00a0controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome","volume":"13","author":"Niedzielin","year":"2001","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.gtc.2021.04.003_bib79","first-page":"631","article-title":"Probiotics as therapy in gastroenterology: a study of physician opinions and recommendations","volume":"44","author":"Williams","year":"2010","journal-title":"J\u00a0Clin Gastroenterol"},{"issue":"Suppl 2","key":"10.1016\/j.gtc.2021.04.003_bib80","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1093\/cid\/civ085","article-title":"Risk and safety of probiotics","volume":"60","author":"Doron","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.gtc.2021.04.003_bib81","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3390\/nu9091021","article-title":"Effects of probiotics, prebiotics, and synbiotics on human health","volume":"9","author":"Markowiak","year":"2017","journal-title":"Nutrients"},{"issue":"2","key":"10.1016\/j.gtc.2021.04.003_bib82","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1079\/NRR200479","article-title":"Dietary modulation of the human colonic microbiota: updating the concept of prebiotics","volume":"17","author":"Gibson","year":"2004","journal-title":"Nutr Res Rev"},{"issue":"Suppl 2","key":"10.1016\/j.gtc.2021.04.003_bib83","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1017\/S0007114510003363","article-title":"Prebiotic effects: metabolic and health benefits","volume":"104","author":"Roberfroid","year":"2010","journal-title":"Br J Nutr"},{"issue":"Suppl 1","key":"10.1016\/j.gtc.2021.04.003_bib84","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/jgh.13700","article-title":"Prebiotic inulin-type fructans and galacto-oligosaccharides: definition, specificity, function, and application in gastrointestinal disorders","volume":"32","author":"Wilson","year":"2017","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.gtc.2021.04.003_bib85","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1365-2036.2008.03911.x","article-title":"Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome","volume":"29","author":"Silk","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.gtc.2021.04.003_bib86","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1080\/10408398.2012.656772","article-title":"Immunological properties of inulin-type fructans","volume":"55","author":"Vogt","year":"2015","journal-title":"Crit Rev Food Sci Nutr"},{"issue":"4","key":"10.1016\/j.gtc.2021.04.003_bib87","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1017\/S0007114515001889","article-title":"Influence of galacto-oligosaccharide mixture (B-GOS) on gut microbiota, immune parameters and metabonomics in elderly persons","volume":"114","author":"Vulevic","year":"2015","journal-title":"Br J Nutr"},{"issue":"5","key":"10.1016\/j.gtc.2021.04.003_bib88","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/apt.13931","article-title":"Metabolic adaptation of colonic microbiota to galactooligosaccharides: a proof-of-concept-study","volume":"45","author":"Mego","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.gtc.2021.04.003_bib89","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/jgh.13471","article-title":"Alterations of gut microbiota in patients with irritable bowel syndrome: a systematic review and meta-analysis","volume":"32","author":"Zhuang","year":"2017","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.gtc.2021.04.003_bib90","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1053\/j.gastro.2018.06.045","article-title":"Effects of prebiotics vs a diet low in FODMAPs in patients with functional gut disorders","volume":"155","author":"Huaman","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2021.04.003_bib91","doi-asserted-by":"crossref","first-page":"2390240","DOI":"10.1155\/2019\/2390240","article-title":"Human milk oligosaccharides: the journey ahead","volume":"2019","author":"Ray","year":"2019","journal-title":"Int J Pediatr"},{"issue":"4","key":"10.1016\/j.gtc.2021.04.003_bib92","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1093\/ajcn\/nqy376","article-title":"Prebiotics in irritable bowel syndrome and other functional bowel disorders in adults: a systematic review and meta-analysis of randomized controlled trials","volume":"109","author":"Wilson","year":"2019","journal-title":"Am J Clin Nutr"},{"issue":"6","key":"10.1016\/j.gtc.2021.04.003_bib93","first-page":"1401","article-title":"Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics","volume":"125","author":"Gibson","year":"1995","journal-title":"J\u00a0Nutr"},{"issue":"33","key":"10.1016\/j.gtc.2021.04.003_bib94","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.3748\/wjg.v18.i33.4563","article-title":"Effect of composite yogurt enriched with acacia fiber and Bifidobacterium lactis","volume":"18","author":"Min","year":"2012","journal-title":"World J Gastroenterol"},{"issue":"4","key":"10.1016\/j.gtc.2021.04.003_bib95","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1443-9573.2004.00176.x","article-title":"Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome","volume":"5","author":"Tsuchiya","year":"2004","journal-title":"Chin J Dig Dis"},{"issue":"3","key":"10.1016\/j.gtc.2021.04.003_bib96","first-page":"156","article-title":"The efficacy of a synbiotic containing Bacillus Coagulans in treatment of irritable bowel syndrome: a randomized placebo-controlled trial","volume":"7","author":"Rogha","year":"2014","journal-title":"Gastroenterol Hepatol Bed Bench"},{"issue":"1","key":"10.1016\/j.gtc.2021.04.003_bib97","first-page":"56","article-title":"Synbiotic containing Bacillus coagulans and fructo-oligosaccharides for functional abdominal pain in children","volume":"8","author":"Saneian","year":"2015","journal-title":"Gastroenterol Hepatol Bed Bench"},{"issue":"7","key":"10.1016\/j.gtc.2021.04.003_bib98","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.3168\/jds.2015-10743","article-title":"Effects of synbiotic fermented milk containing Lactobacillus acidophilus La-5 and Bifidobacterium animalis ssp. lactis BB-12 on the fecal microbiota of adults with irritable bowel syndrome: a randomized double-blind, placebo-controlled trial","volume":"99","author":"Bogovic Matijasic","year":"2016","journal-title":"J\u00a0Dairy Sci"},{"issue":"5","key":"10.1016\/j.gtc.2021.04.003_bib99","doi-asserted-by":"crossref","first-page":"439","DOI":"10.5152\/tjg.2016.16301","article-title":"Efficacy of synbiotic, probiotic, and prebiotic treatments for irritable bowel syndrome in children: a randomized controlled trial","volume":"27","author":"Basturk","year":"2016","journal-title":"Turk J Gastroenterol"},{"issue":"2","key":"10.1016\/j.gtc.2021.04.003_bib100","first-page":"179","article-title":"An evidence-based systematic review of spearmint by the natural standard research collaboration","volume":"7","author":"Ulbricht","year":"2010","journal-title":"J\u00a0Diet Suppl"},{"issue":"6","key":"10.1016\/j.gtc.2021.04.003_bib101","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/apt.14519","article-title":"Review article: the physiological effects and safety of peppermint oil and its efficacy in irritable bowel syndrome and other functional disorders","volume":"47","author":"Chumpitazi","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.gtc.2021.04.003_bib102","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12906-018-2409-0","article-title":"The impact of peppermint oil on the irritable bowel syndrome: a meta-analysis of the pooled clinical data","volume":"19","author":"Alammar","year":"2019","journal-title":"BMC Complement Altern Med"},{"issue":"6","key":"10.1016\/j.gtc.2021.04.003_bib103","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/MCG.0b013e3182a88357","article-title":"Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis","volume":"48","author":"Khanna","year":"2014","journal-title":"J\u00a0Clin Gastroenterol"},{"issue":"1","key":"10.1016\/j.gtc.2021.04.003_bib104","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/j.gastro.2019.08.026","article-title":"Efficacy and safety of peppermint oil in a randomized, double-blind trial of patients with irritable bowel syndrome","volume":"158","author":"Weerts","year":"2020","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.gtc.2021.04.003_bib105","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s10620-015-3858-7","article-title":"A\u00a0novel delivery system of peppermint oil is an effective therapy for irritable bowel syndrome symptoms","volume":"61","author":"Cash","year":"2016","journal-title":"Dig Dis Sci"},{"issue":"3\u20134","key":"10.1016\/j.gtc.2021.04.003_bib106","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10354-012-0169-x","article-title":"STW 5 (Iberogast(R))--a safe and effective standard in the treatment of functional gastrointestinal disorders","volume":"163","author":"Ottillinger","year":"2013","journal-title":"Wien Med Wochenschr"},{"issue":"Suppl 5","key":"10.1016\/j.gtc.2021.04.003_bib107","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.phymed.2006.08.004","article-title":"Spasmolytic and tonic effect of Iberogast (STW 5) in intestinal smooth muscle","volume":"13","author":"Ammon","year":"2006","journal-title":"Phytomedicine"},{"issue":"Suppl 1","key":"10.1016\/j.gtc.2021.04.003_bib108","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000485456","article-title":"Mechanism of action of STW 5 in functional dyspepsia and IBS: the origin of multi-target","volume":"35","author":"Allescher","year":"2017","journal-title":"Dig Dis"},{"issue":"4","key":"10.1016\/j.gtc.2021.04.003_bib109","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/J157v04n04_05","article-title":"Iberis amara L. and Iberogast--results of a systematic review concerning functional dyspepsia","volume":"4","author":"Melzer","year":"2004","journal-title":"J\u00a0Herb Pharmacother"},{"issue":"Suppl 1","key":"10.1016\/j.gtc.2021.04.003_bib110","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000485410","article-title":"STW 5 (Iberogast) therapy in gastrointestinal functional disorders","volume":"35","author":"Malfertheiner","year":"2017","journal-title":"Dig Dis"},{"issue":"3","key":"10.1016\/j.gtc.2021.04.003_bib111","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2036.2004.01859.x","article-title":"Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial","volume":"19","author":"Madisch","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2021.04.003_bib112","first-page":"61","article-title":"The importance of intestinal glutamine metabolism in maintaining a healthy gastrointestinal tract and supporting the body's response to injury and illness","volume":"22","author":"Klimberg","year":"1990","journal-title":"Surg Annu"},{"issue":"5","key":"10.1016\/j.gtc.2021.04.003_bib113","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1097\/01.CCM.0000162680.52397.97","article-title":"Intestinal permeability and systemic infections in critically ill patients: effect of glutamine","volume":"33","author":"De-Souza","year":"2005","journal-title":"Crit Care Med"},{"issue":"12","key":"10.1016\/j.gtc.2021.04.003_bib114","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1038\/ajg.2011.257","article-title":"The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype","volume":"106","author":"Bertiaux-Vandaele","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.gtc.2021.04.003_bib115","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1136\/gut.2009.181834","article-title":"MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome","volume":"59","author":"Zhou","year":"2010","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.gtc.2021.04.003_bib116","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1136\/gutjnl-2017-315136","article-title":"Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome","volume":"68","author":"Zhou","year":"2019","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.gtc.2021.04.003_bib117","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1136\/gutjnl-2018-317438","article-title":"Efficacy of glutamine in postinfection IBS","volume":"68","author":"Ford","year":"2019","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.gtc.2021.04.003_bib118","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.2527\/2004.8261764x","article-title":"Spray-dried plasma improves growth performance and reduces inflammatory status of weaned pigs challenged with enterotoxigenic Escherichia coli K88","volume":"82","author":"Bosi","year":"2004","journal-title":"J\u00a0Anim Sci"},{"issue":"14","key":"10.1016\/j.gtc.2021.04.003_bib119","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1097\/QAD.0b013e328362e54c","article-title":"Oral serum-derived bovine immunoglobulin improves duodenal immune reconstitution and absorption function in patients with HIV enteropathy","volume":"27","author":"Asmuth","year":"2013","journal-title":"AIDS"},{"issue":"7","key":"10.1016\/j.gtc.2021.04.003_bib120","first-page":"1312","article-title":"Spray-dried porcine plasma influences intestinal barrier function, inflammation, and diarrhea in weaned pigs","volume":"141","author":"Peace","year":"2011","journal-title":"J\u00a0Nutr"},{"key":"10.1016\/j.gtc.2021.04.003_bib122","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.2147\/PPA.S134792","article-title":"Impact of serum-derived bovine immunoglobulin\/protein isolate therapy on irritable bowel syndrome and inflammatory bowel disease: a survey of patient perspective","volume":"11","author":"Shaw","year":"2017","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.gtc.2021.04.003_bib123","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4137\/CGast.S13200","article-title":"Evaluation of serum-derived bovine immunoglobulin protein isolate in subjects with diarrhea-predominant irritable bowel syndrome","volume":"6","author":"Wilson","year":"2013","journal-title":"Clin Med Insights Gastroenterol"},{"issue":"5","key":"10.1016\/j.gtc.2021.04.003_bib124","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1053\/j.gastro.2018.11.069","article-title":"Current practice in the diagnosis of bile acid diarrhea","volume":"156","author":"Vijayvargiya","year":"2019","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.gtc.2021.04.003_bib125","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1136\/gut.16.11.894","article-title":"Bile acids and colonic motility in the rabbit and the human","volume":"16","author":"Kirwan","year":"1975","journal-title":"Gut"},{"issue":"12","key":"10.1016\/j.gtc.2021.04.003_bib126","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1136\/gutjnl-2015-309889","article-title":"Biomarkers for bile acid diarrhoea in functional bowel disorder with diarrhoea: a systematic review and meta-analysis","volume":"65","author":"Valentin","year":"2016","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.gtc.2021.04.003_bib127","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11894-018-0615-z","article-title":"Update on bile acid malabsorption: finally ready for prime time?","volume":"20","author":"Vijayvargiya","year":"2018","journal-title":"Curr Gastroenterol Rep"},{"issue":"1","key":"10.1016\/j.gtc.2021.04.003_bib128","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/gutjnl-2013-305965","article-title":"Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS","volume":"64","author":"Bajor","year":"2015","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.gtc.2021.04.003_bib129","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/apt.13065","article-title":"Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea-predominant irritable bowel syndrome","volume":"41","author":"Camilleri","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"13","key":"10.1016\/j.gtc.2021.04.003_bib130","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1016\/j.cgh.2020.02.027","article-title":"Effects of colesevelam on bowel symptoms, biomarkers, and colonic mucosal gene expression in patients with bile acid diarrhea in a randomized trial","volume":"18","author":"Vijayvargiya","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.gtc.2021.04.003_bib131","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/j.1365-2036.2009.04081.x","article-title":"Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome","volume":"30","author":"Wedlake","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.gtc.2021.04.003_bib132","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00109-007-0192-3","article-title":"Overactivity of the intestinal endocannabinoid system in celiac disease and in methotrexate-treated rats","volume":"85","author":"D'Argenio","year":"2007","journal-title":"J\u00a0Mol Med (Berl)"},{"issue":"8","key":"10.1016\/j.gtc.2021.04.003_bib133","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1136\/gut.2008.148791","article-title":"Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects","volume":"57","author":"Izzo","year":"2008","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.gtc.2021.04.003_bib134","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/j.1365-2982.2006.00819.x","article-title":"Involvement of cannabinoid receptors in inflammatory hypersensitivity to colonic distension in rats","volume":"18","author":"Sanson","year":"2006","journal-title":"Neurogastroenterol Motil"},{"issue":"6","key":"10.1016\/j.gtc.2021.04.003_bib135","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.coph.2007.08.008","article-title":"The endocannabinoid system and gut-brain signalling","volume":"7","author":"Storr","year":"2007","journal-title":"Curr Opin Pharmacol"},{"issue":"9","key":"10.1016\/j.gtc.2021.04.003_bib136","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/j.1365-2982.2007.00977.x","article-title":"The cannabinoid CB(2) receptor: a good friend in the gut","volume":"19","author":"Izzo","year":"2007","journal-title":"Neurogastroenterol Motil"},{"issue":"4","key":"10.1016\/j.gtc.2021.04.003_bib137","doi-asserted-by":"crossref","first-page":"358-e169","DOI":"10.1111\/j.1365-2982.2011.01874.x","article-title":"Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea","volume":"24","author":"Wong","year":"2012","journal-title":"Neurogastroenterol Motil"},{"issue":"5","key":"10.1016\/j.gtc.2021.04.003_bib138","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1053\/j.gastro.2011.07.036","article-title":"Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome","volume":"141","author":"Wong","year":"2011","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.gtc.2021.04.003_bib139","doi-asserted-by":"crossref","first-page":"e85073","DOI":"10.1371\/journal.pone.0085073","article-title":"Endocannabinoid and cannabinoid-like fatty acid amide levels correlate with pain-related symptoms in patients with IBS-D and IBS-C: a pilot study","volume":"8","author":"Fichna","year":"2013","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.gtc.2021.04.003_bib140","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/apt.13958","article-title":"Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome","volume":"45","author":"Cremon","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2021.04.003_bib141","article-title":"Pharmacology, clinical effects, and therapeutic potential of cannabinoids for gastrointestinal and liver diseases","volume":"13","author":"Maselli","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.gtc.2021.04.003_bib142","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1080\/00207450802328607","article-title":"Melatonin and melatonergic drugs on sleep: possible mechanisms of action","volume":"119","author":"Srinivasan","year":"2009","journal-title":"Int J Neurosci"},{"issue":"3","key":"10.1016\/j.gtc.2021.04.003_bib143","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1080\/15622970600571822","article-title":"Melatonin in mood disorders","volume":"7","author":"Srinivasan","year":"2006","journal-title":"World J Biol Psychiatry"},{"issue":"3","key":"10.1016\/j.gtc.2021.04.003_bib144","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/apt.13677","article-title":"Effects of disturbed sleep on gastrointestinal and somatic pain symptoms in irritable bowel syndrome","volume":"44","author":"Patel","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.gtc.2021.04.003_bib145","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1053\/j.gastro.2007.09.039","article-title":"Sleep deprivation is hyperalgesic in patients with gastroesophageal reflux disease","volume":"133","author":"Schey","year":"2007","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.gtc.2021.04.003_bib146","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/j.1365-2036.2005.02673.x","article-title":"Melatonin improves bowel symptoms in female patients with irritable bowel syndrome: a double-blind placebo-controlled study","volume":"22","author":"Lu","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.gtc.2021.04.003_bib147","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1136\/gut.2004.062034","article-title":"Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomised, double blind, placebo controlled study","volume":"54","author":"Song","year":"2005","journal-title":"Gut"}],"container-title":["Gastroenterology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855321004696?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855321004696?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:30:37Z","timestamp":1760178637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889855321004696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":140,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0889855321004696"],"URL":"https:\/\/doi.org\/10.1016\/j.gtc.2021.04.003","relation":{},"ISSN":["0889-8553"],"issn-type":[{"value":"0889-8553","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medical Therapies for Diarrhea-Predominant Irritable Bowel Syndrome","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gtc.2021.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}